GE HealthCare Technologies Inc. (NASDAQ:GEHC)
| Market Cap | $36.46B+3.1% |
| Revenue (ttm) | $21.64B+6.9% |
| Net Income | $2.17B-2.3% |
| EPS | $4.74-2.1% |
| Shares Out | 452.14M |
| PE Ratio | 17.01 |
| Forward PE | 14.59 |
| Dividend | $0.14(0.18%) |
| Ex-Dividend Date | Oct 23, 2026 |
| Volume | 3,770,992 |
| Open | $82.53 |
| Previous Close | $81.89 |
| Day's Range | $80.30 - $83.07 |
| 52-Week Range | $58.75 - $89.77 |
| Beta | 0.77 |
| Analysts | Buy |
| Price Target | $81.22(+0.72%) |
| Earnings Date | Feb 3, 2027 |
About GEHC
GE HealthCare Technologies Inc. is a global medical technology company that creates, manufactures, and markets a diverse range of medical devices, services, and integrated digital solutions. These offerings are designed to assist in the diagnosis, treatment, and ongoing monitoring of patients. The company boasts an extensive international presence, serving markets across the United States, Canada, Europe, the Middle East, Africa, China, Taiwan, Mongolia, and Hong Kong, among other regions. Its operations are structured across four primary business divisions: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics. The Imaging division specializes in advanced diagnostic imaging technologies, including systems for molecular imaging, Computed Tomography (CT) scans, Magnetic Resonance (MR) imaging, image-guided therapy, and X-ray, alongside specialized women's health products. The Ultrasound segment delivers a comprehensive suite of ultrasound solutions utilized for the screening, diagnosis, treatment, and monitoring of various diseases. These applications span radiology, primary care, women's health, cardiovascular diagnostics, point-of-care, and portable handheld devices, in addition to products supporting surgical visualization and guidance. The Patient Care Solutions segment is dedicated to providing essential medical devices, consumable products, services, and digital platforms. Its portfolio encompasses patient monitoring, anesthesia delivery and respiratory care, diagnostic cardiology, and maternal-infant care products. The Pharmaceutical Diagnostics segment supplies specialized diagnostic agents to the radiology and nuclear medicine industries. These include contrast media pharmaceuticals, administered to patients prior to scans like CT, angiography, X-ray, and MR, to enhance the visibility of internal tissues and structures. It also offers molecular imaging agents, or radiopharmaceuticals – molecular tracers labeled with radioisotopes – injected into patients for advanced diagnostic imaging applications such as Single-Photon Emission Computed Tomography (SPECT), Positron Emission Tomography (PET), and specific ultrasound procedures. Established in 2022, GE HealthCare Technologies Inc. maintains its corporate headquarters in Chicago, Illinois.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
Analyst consensus
8 firms rating GEHC in the last 3 months, one vote each. Issuer-paid research is not counted.
Next catalysts
- Feb 3, 2027Earnings report
$GEHC stock is featured in our Congress Trading, and Insider Trades datasets.
→ All Stock ListsCongress Trading
Recent trades of GEHC by members of U.S. Congress
| Ro KhannaHouse / D | Purchase$1.00K – $15.00K | Sep 11, 2026 |
| Ro KhannaHouse / D | Purchase$1.00K – $15.00K | Jul 2, 2026 |
| Alan ArmstrongSenate / R | Purchase$1.00K – $15.00K | Mar 27, 2026 |
| Terri SewellHouse / D | Sale$1.00K – $15.00K | Mar 25, 2026 |
| Austin ScottHouse / R | Sale$1.00K – $15.00K | Mar 27, 2025 |
| Michael T. McCaulHouse / R | Sale$100.00K – $250.00K | Jan 20, 2023 |
Recently reported changes in GEHC holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by GEHC's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
GEHC Estimated quarterly lobbying spending
Source: U.S. Senate LDA
GEHC Revenue by Segment or Geography
| AIS | $3.87B | 70.24% |
| PDx | $846.00M | 15.34% |
| PCS | $793.00M | 14.38% |
| Other | $2.00M | 0.04% |
As of: Q3 2026 (Sep 30, 2026) · Source: SEC EDGAR (10-Q)
U.S. Patents
New GEHC patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to GEHC from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in GEHC
| VOOVanguard S&P 500 ETF | $919.04M |
| VTIVanguard Morningstar Total Stock Market ETF | $866.64M |
| QQQInvesco QQQ Trust, Series 1 | $794.36M |
| VOVanguard Morningstar Mid-Cap ETF | $738.84M |
| IVViShares Core S&P 500 ETF | $498.31M |
| SPYState Street SPDR S&P 500 ETF | $450.77M |
Estimated from each fund’s disclosed top holdings × AUM
Bull Case vs Bear Case
AI-generated from GEHC’s recent data — informational, not investment advice
What’s Behind the Score
News check: Multiple positive clinical and regulatory achievements including FDA approval, Phase 3 advancement, and new AI products offset neutral guidance updates.
Recent Insider Activity
Frequently Asked Questions
ETFs that hold this stock
| CSD | Invesco S&P Spin-Off ETF | 9.41% |
| MVAL | VanEck ETF Trust - VanEck Morningstar Wide Moat Value ETF | 5.11% |
| FDHT | FIDELITY DIGITAL HEALTH ETF | 4.76% |
| HEAL | Global X HealthTech ETF | 4.66% |
| IHI | iShares U.S. Medical Devices ETF | 4.62% |
| FEMD | First Eagle Mid Cap Equity ETF | 2.91% |
| MOAT | VanEck Morningstar Wide Moat ETF | 2.90% |
| CNAV | Mohr Company Nav ETF | 2.59% |
| HWGV | Hotchkis & Wiley Global Value Fund | 2.47% |
| MDEV | First Trust Indxx Medical Devices ETF | 2.35% |
| FHH.TO | First Trust AlphaDEX U.S. Health Care Sector Index ETF | 2.30% |
| FXH | First Trust Health Care AlphaDEX Fund | 2.29% |
Weight is the stock’s share of each fund’s holdings.
